

In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against *Aspergillus* and *Candida*

ANTHONY CACCIAPUOTI,* DAVID LOEBENBERG, ERIK CORCORAN,† FRED MENZEL, JR.,
EUGENE L. MOSS, JR., CHRISTINE NORRIS, MONIKA MICHALSKI, KIMBERLY RAYNOR,
JUDITH HALPERN, CARA MENDRICK, BRIAN ARNOLD, BARRY ANTONACCI,
RAULO PARMEGIANI, TAISA YAROSH-TOMAINO, GEORGE H. MILLER,†
AND ROBERTA S. HARE

Schering-Plough Research Institute, Kenilworth, New Jersey 07033-1300

Received 18 January 2000/Returned for modification 16 February 2000/Accepted 28 April 2000

SCH 56592 (posaconazole), a new triazole antifungal agent, was tested in vitro, and its activity was compared to that of itraconazole against 39 *Aspergillus* strains and to that of fluconazole against 275 *Candida* and 9 *Cryptococcus* strains. The SCH 56592 MICs for *Aspergillus* ranged from ≤ 0.002 to 0.5 $\mu\text{g/ml}$, and those of itraconazole ranged from ≤ 0.008 to 1 $\mu\text{g/ml}$. The SCH 56592 MICs for *Candida* and *Cryptococcus* strains ranged from ≤ 0.004 to 16 $\mu\text{g/ml}$, and those of fluconazole ranged from ≤ 0.062 to > 64 $\mu\text{g/ml}$. SCH 56592 showed excellent activity against *Aspergillus fumigatus* and *Aspergillus flavus* in a pulmonary mouse infection model. When administered therapeutically, the 50% protective doses (PD_{50} s) of SCH 56592 ranged from 3.6 to 29.9 mg/kg of body weight, while the PD_{50} s of SCH 56592 administered prophylactically ranged from 0.9 to 9.0 mg/kg; itraconazole administered prophylactically was ineffective (PD_{50} s, > 75 mg/kg). SCH 56592 was also very efficacious against fluconazole-susceptible, -susceptible dose-dependent, or -resistant *Candida albicans* strains in immunocompetent or immunocompromised mouse models of systemic infection. The PD_{50} s of SCH 56592 administered therapeutically ranged from 0.04 to 15.6 mg/kg, while the PD_{50} s of SCH 56592 administered prophylactically ranged from 1.5 to 19.4 mg/kg. SCH 56592 has excellent potential for therapy against serious *Aspergillus* or *Candida* infections.

Of the estimated 100,000 known species of fungi, only about 180 have been shown to cause disease in humans, and only about 10% of these are encountered in most clinical settings (8). However, fungal infections have substantially increased over the past two decades, and invasive forms are important causes of morbidity and mortality (2, 16). The major increase in fungal infections is related to increased numbers of immunocompromised patients including those with human immunodeficiency virus infection-AIDS or cancer and bone marrow or solid organ transplant recipients, who are at risk of developing invasive fungal infections (5, 7, 12, 16). Disseminated candidiasis, pulmonary aspergillosis, and mycoses caused by emerging opportunistic fungi are the most common of these serious mycoses (7, 16, 38). As a result, there is a developing consensus that prophylactic therapy should be used for these high-risk patients (12). Fluconazole (FLC) is used for prevention of fungal infections in some of these patients, but it is not active against *Aspergillus* or other filamentous fungi. However, there is great concern about the development of resistant *Candida* due to prophylactic use of FLC (4, 10, 15, 18, 23, 35, 37). Clearly, alternative antifungal agents are needed for both therapeutic and prophylactic use. SCH 56592 (SCH; posaconazole) is a new triazole antifungal agent with broad-spectrum activity against fungi including strains of *Aspergillus* and *Candida* resistant to FLC (9, 11, 19, 24, 30, 33). This report describes the in vitro activity of SCH against *Aspergillus* and *Candida* and its

efficacy in clinically relevant experimental infection models in mice with both prophylactic and therapeutic dosing regimens.

(Preliminary reports of this research were presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., 17 to 20 September 1995 [A. Cacciapuoti, R. Parmegiani, D. Loebenberg, B. Antonacci, E. L. Moss, Jr., F. Menzel, Jr., C. Norris, R. S. Hare, and G. H. Miller, Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F66, p. 124, 1995], and the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September 1998 [D. Loebenberg, F. Menzel, Jr., E. Corcoran, K. Raynor, J. Halpern, A. F. Cacciapuoti, and R. S. Hare, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. J-63, p. 469, 1998].)

MATERIALS AND METHODS

Mice. White male CF1 mice from Charles River Laboratories (Wilmington, Mass.) were used in these studies. At the time of infection the mice in the pulmonary infection studies weighed 16 to 18 g and those in the systemic infection studies weighed 18 to 20 g.

Antifungal agents. SCH was prepared at Schering-Plough Research Institute, Kenilworth, N.J., either as a micronized powder or as the clinically formulated suspension. For in vitro susceptibility tests the powder was dissolved in dimethyl sulfoxide, while for in vivo studies it was prepared as a suspension in 0.4% (wt/vol) methylcellulose (MC) containing 0.5% (wt/vol) polysorbate 80 and 0.9% (wt/vol) NaCl. The clinical suspension was diluted as needed in sterile water for injection (sWFI) and used for some in vivo studies. Both forms of SCH were previously tested in our laboratory and were found to have the same in vivo efficacy. FLC powder and Diflucan oral suspension were obtained from Pfizer, Inc., Kent, England. For in vivo use, FLC powder was prepared in MC and Diflucan was diluted as needed in sWFI. Itraconazole (ITC) powder and Sporanox oral solution were obtained from Janssen Pharmaceutica Inc., Beerse, Belgium. For in vivo use only Sporanox was used, and it was diluted as needed in hydroxypropyl- β -cyclodextrin (HP β CD; 40% [wt/vol] in water; Cerestar USA, Inc., Hammond, Ind.).

In vitro antifungal activity. All strains of *Aspergillus*, *Candida*, and *Cryptococcus* were from the Schering-Plough Research Institute fungal culture collection. The MICs for *Candida* and *Cryptococcus* strains were determined by the broth

* Corresponding author. Mailing address: Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033-1300. Phone: (908) 740-3139. Fax: (908) 740-3918. E-mail: anthony.cacciapuoti@spcorp.com.

† Present address: Research & Development, Microcide Pharmaceuticals Inc., Mountain View, CA 94043.

TABLE 1. In vitro activities of SCH, ITC, and FLC against *Aspergillus*, *Candida*, and *Cryptococcus*

Species	No. of isolates	MIC ($\mu\text{g/ml}$)								
		SCH			ITC			FLC		
		Range	50%	90%	Range	50%	90%	Range	50%	90%
<i>A. flavus</i>	11	≤ 0.002 –0.125	0.008	0.125	0.008–0.25	0.125	0.25	ND ^a	ND	ND
<i>A. fumigatus</i>	17	≤ 0.002 –0.062	≤ 0.002	0.031	0.004–0.25	0.125	0.25	ND	ND	ND
<i>Aspergillus</i> species ^b	11	≤ 0.002 –0.5	0.016	0.5	≤ 0.008 –1	0.125	0.5	ND	ND	ND
<i>C. albicans</i>	156	≤ 0.004 –16	≤ 0.004	0.125	ND	ND	ND	0.062–>64	0.125	16
<i>C. tropicalis</i>	20	≤ 0.004 –8	≤ 0.016	2	ND	ND	ND	0.125–>64	0.25	>64
<i>C. glabrata</i>	20	≤ 0.016 –2	0.25	1	ND	ND	ND	0.5–>64	4	64
<i>C. krusei</i>	20	0.062–0.5	0.25	0.5	ND	ND	ND	8–64	32	64
<i>Candida</i> species ^c	59	≤ 0.004 –1	≤ 0.016	0.25	ND	ND	ND	≤ 0.062 –>64	0.25	16
<i>C. neoformans</i>	9	≤ 0.016 –0.5	0.062	ND	ND	ND	ND	≤ 0.062 –16	2	ND

^a ND, not determined.

^b Includes the following species and number of strains: *A. niger*, $n = 5$; *A. terreus*, $n = 4$; *A. nidulans*, $n = 1$; species not identified, $n = 1$.

^c Includes the following species and number of strains: *C. kefyr*, $n = 7$; *C. parapsilosis*, $n = 7$; *C. guilliermondii*, $n = 6$; *C. dubliniensis*, $n = 5$; *C. lusitanae*, $n = 5$; *C. lambica*, $n = 3$; *C. rugosa*, $n = 3$; *C. famata*, $n = 2$; *C. inconspicua*, $n = 2$; *C. pseudotropicalis*, $n = 1$; *C. stellatoidea*, $n = 1$; species not identified, $n = 17$.

microdilution method according to the procedures of the National Committee for Clinical Laboratory Standards (NCCLS) described in document M27-A, Reference Method for Broth Dilution Susceptibility Testing of Yeasts (26), and those for *Aspergillus* strains were determined by the procedures described in NCCLS document M38-P, Reference Method for Broth Dilution Susceptibility Testing of Conidium-Forming Filamentous Fungi (27).

Therapeutic activity against pulmonary aspergillosis. *Aspergillus fumigatus* strains ND152, ND158, ND159, and ND164 and *Aspergillus flavus* strains ND83, ND134, ND149, and ND168 were grown on malt extract agar for 13 days at 25°C in an inhalation chamber. Mice were compromised with subcutaneous cortisone acetate (100 mg/kg of body weight once daily on the day before infection and the following 2 days) and were exposed to a spore cloud for 0.5 to 1 min in the chamber on the second day of compromise (day 0), as described previously (20). Oral administration of SCH (dose range, 40 to 2.5 mg/kg; 10 mice per dose) began 24 h postinfection, and SCH was given once daily for 4 days. Control mice were administered MC. The 50% protective dose (PD₅₀), defined as the dose which allowed 50% survival, was calculated from the data for the surviving mice on day 7 postinfection by the Hill equation (1).

Prophylactic activity against pulmonary aspergillosis. *A. flavus* ND83 or *A. fumigatus* ND152 or ND158 was grown as described above. Mice were compromised with cortisone acetate and were infected as described above. Cortisone acetate was also administered on days 6 and 12 postinfection to maintain immunosuppression. Oral administration of drugs (25 to 0.025 mg/kg) to groups of eight mice was once (SCH) or three times (ITC) daily beginning at 24 h preinfection (prophylactic) and continuing through day 7 postinfection. Control mice were administered MC or HP β CD. PD₅₀s were determined as described above by use of the data for the surviving mice on day 7 postinfection. Fungal counts in the lungs of mice that survived at the termination of the experiments were determined by spreading aliquots of homogenized suspensions onto Sabouraud dextrose agar (SDA).

Therapeutic activity against systemic candidiasis. *Candida albicans* strains C43, C65, C72, C84, C260, C284, C286, C288, and C342 were grown for 48 h on SDA, and inocula were prepared as described previously (3). Normal mice or immunocompromised mice (which were immunocompromised by exposure to 500 rads 3 days prior to infection in a Shepherd Mark I cesium gamma irradiator) were infected on day 0 by injecting 2.5×10^6 to 1×10^7 CFU as a saline suspension into the tail vein. Groups of 10 mice each were treated with SCH (100 to 0.063 mg/kg) or FLC (200 to 0.63 mg/kg) orally once daily for 4 days beginning at 4 h postinfection. Control mice were administered MC or sWFI. PD₅₀s, calculated as described above, were determined by use of the data for the surviving mice on day 4 postinfection. Survivors were killed 24 h after the last treatment, and the fungal counts in the kidneys were determined as described previously (3).

Prophylactic activity against systemic candidiasis. *C. albicans* strains C43, C284, C288, and C310 were grown as described above. Groups of 10 mice each were immunocompromised, infected (5×10^6 CFU) as described above, and given SCH (50 to 0.025 mg/kg) or FLC (250 to 0.025 mg/kg) orally once daily beginning at 24 h preinfection and continuing through day 7 postinfection. Control mice were administered sWFI. PD₅₀s were calculated by use of the data for the surviving mice on day 7 postinfection as described above.

Statistical analysis. A logistic model was used to determine differences between PD₅₀s by using their 95% confidence bounds. A chi-square test or logistic model was used to determine if the levels of survival among mice in the treatment groups were significantly different from those among mice in the control group. Comparison of survival-versus-time curves in prophylactic activity experiments with mice to determine efficacy differences between drugs at various dose

levels was done by log-rank tests. A chi-square test was performed to show significant differences between treatment groups in the clearance of *Aspergillus* from the lungs of the mice.

Statement of animal care and use. These studies were carried out in accordance with the *Guide to the Care and Use of Laboratory Animals* of the National Institutes of Health (28) and the Animal Welfare Act in an Association for Assessment Accreditation of Laboratory Animal Care-accredited program.

RESULTS

In vitro antifungal activity. The in vitro activities of SCH and ITC against 39 strains of *Aspergillus* are shown in Table 1. The MICs of SCH and ITC ranged from ≤ 0.002 to 0.5 and ≤ 0.008 to 1 $\mu\text{g/ml}$, respectively. Against *A. flavus*, *A. fumigatus*, and other *Aspergillus* species, SCH was overall more active (MICs at which 50% of isolates are inhibited [MIC₅₀s], 0.008, ≤ 0.002 , and 0.016 $\mu\text{g/ml}$, respectively; MIC₉₀s, 0.125, 0.031, and 0.5 $\mu\text{g/ml}$, respectively) than ITC (MIC₅₀s, 0.125 $\mu\text{g/ml}$; MIC₉₀s, 0.25, 0.25, and 0.5 $\mu\text{g/ml}$, respectively).

The in vitro activities of SCH and FLC against 275 strains of *Candida*, including strains which were susceptible (S), susceptible dose-dependent (S-DD), or resistant (R) to FLC on the basis of NCCLS breakpoints (26), are also shown in Table 1. The MICs of SCH and FLC ranged from ≤ 0.004 to 16 and ≤ 0.062 to >64 $\mu\text{g/ml}$, respectively. The potent activity of SCH against FLC-S, FLC-S-DD, and FLC-R strains was reflected in the MIC₉₀s of SCH for *C. albicans*, *C. tropicalis*, *C. glabrata*, *C. krusei*, and other *Candida* species (SCH MIC₉₀s, 0.125, 2, 1, 0.5, and 0.25 $\mu\text{g/ml}$, respectively compared to those of FLC (16, >64, 64, 64, and 16 $\mu\text{g/ml}$, respectively). The only resistance to SCH observed was by one strain of *C. albicans*, for which the MIC was 16 $\mu\text{g/ml}$, and two strains of *C. albicans* and one of *C. tropicalis*, for which the MICs were 8 $\mu\text{g/ml}$.

SCH was also more active than FLC against nine strains of *Cryptococcus neoformans* (MIC₅₀s, 0.062 and 2 $\mu\text{g/ml}$, respectively) (Table 1).

Therapeutic activity against pulmonary aspergillosis. The in vivo efficacy of SCH administered therapeutically against pulmonary aspergillosis in immunocompromised mice was examined by using four strains each of *A. fumigatus* and *A. flavus*. The MICs of SCH were ≤ 0.002 $\mu\text{g/ml}$ for *A. fumigatus* ND158, ND159, and ND164 and *A. flavus* ND134 and ND168, while the SCH MICs were 0.0625, 0.008, and 0.125 $\mu\text{g/ml}$ for *A. fumigatus* ND152 and *A. flavus* ND83 and ND149, respectively. PD₅₀s on the basis of the data for the surviving mice at 7 days postinfection ranged from 3.6 to 29.9 mg/kg against *A. fumiga-*

TABLE 2. Efficacy of therapeutic and prophylactic administration of SCH against pulmonary *Aspergillus* infections in immunocompromised mice

Strain	PD ₅₀ (mg/kg) on day 7		
	Therapeutic administration of SCH ^a	Prophylactic administration of ^b :	
		SCH	ITC
<i>A. fumigatus</i>			
ND152	3.6	2.2, 0.9 ^c	>75, >75 ^c
ND158	29.9	2.6	>75
ND159	10.9	ND ^d	ND
ND164	22.2	ND	ND
<i>A. flavus</i>			
ND83	5.7	3.9, 9.0 ^c	>75, >75 ^c
ND134	4.8	ND	ND
ND149	6.5	ND	ND
ND168	5.6	ND	ND

^a ITC was not tested therapeutically.
^b The PD₅₀ was based on the total daily dose.
^c Results from experiments 1 and 2.
^d ND, not done.

and from 4.8 to 6.5 mg/kg against *A. flavus* (Table 2), and the survival results showed significant differences between treatment groups and controls ($P < 0.05$). The highest PD₅₀s were observed against *A. fumigatus* ND158 (29.9 mg/kg) and ND164 (22.2 mg/kg), although these strains were clearly susceptible to SCH in vitro. All control mice died within 3 to 8 days postinfection.

Prophylactic activity against pulmonary aspergillosis. The in vivo efficacy of SCH against *Aspergillus* in mice was further investigated with a clinically relevant infection model characterized by prophylactic administration preinfection, followed by continued treatment postinfection. SCH administered once daily was compared to ITC administered three times daily, and the results are shown in Table 2. SCH (PD₅₀ range, 0.9 to 9.0 mg/kg) was efficacious against strains of *A. fumigatus* and *A. flavus*, while ITC failed to protect the mice (PD₅₀s, >75 mg/kg). The survival-versus-time graph for *A. fumigatus* ND152 is shown in Fig. 1. Against this strain, SCH at 25 and 10 mg/kg protected 100% of mice for 19 days, while control mice and those administered ITC (total daily dose, 75 mg/kg) were all dead by days 4 to 6. SCH at 25, 10, 5, 2.5, and 1 mg/kg was significantly more effective than ITC at 75 mg/kg ($P < 0.01$). The survival-versus-time graphs for the other *Aspergillus* strains tested (data not shown) showed that SCH had significant efficacy compared to that of ITC at 75 mg/kg ($P < 0.01$).

SCH also appeared to be more effective in clearing the infection from the lungs of mice infected with *A. fumigatus* than those of mice infected with *A. flavus*. At 25 and 10 mg/kg, the lungs of 65% of mice infected with *A. fumigatus* ND152 or ND158 were sterilized, but the lungs of only 3% (one mouse) of those infected with *A. flavus* ND83 were sterilized ($P < 0.01$) (Table 3). This differential effect against *A. fumigatus* and *A. flavus* was also evident at the lower doses.

Therapeutic activity against systemic candidiasis. The in vivo efficacy of SCH administered therapeutically against systemic candidiasis was examined in immunocompetent and/or immunocompromised mouse models by using nine strains of *C. albicans*. Included were five FLC-S strains (strains C43, C65, C84, C72, and C286, for which FLC MICs were 0.125, 0.25, 0.25, 0.25, and 4 μg/ml, respectively), two FLC-S-DD strains (strains C288 and C342, for which FLC MICs were 32 and 16




FIG. 1. Effects of SCH (administered orally once daily) and ITC (administered orally three times daily) administered in a prophylactic regimen 1 day preinfection to 7 days postinfection on survival of immunocompromised mice infected (by 1 min of exposure to spores on day 0) with *A. fumigatus* ND152 by the pulmonary route. Total daily doses (in milligrams per kilogram) are indicated. Controls were administered MC or HPβCD.

μg/ml, respectively), and two FLC-R strains (strains C260 and C284, for which FLC MICs were >64 μg/ml). The SCH MICs for the strains ranged from ≤0.004 to 0.5 μg/ml; however, the SCH MIC for C260 was 16 μg/ml. The results of these in vivo studies are shown in Table 4. SCH was active against all strains tested, but the PD₅₀ against C260 (15.6 mg/kg) was higher than those against the other eight strains (PD₅₀ range, 0.04 to 7.1 mg/kg). FLC was active against the FLC-S strains (PD₅₀ range, 0.9 to 6.1 mg/kg), less active against the FLC-S-DD strains (PD₅₀s, 25 and 30.5 mg/kg, respectively), and inactive against the FLC-R strains (PD₅₀s, 342 and 417 mg/kg, respectively). In these studies, 80 to 100% of control mice were dead by 4 days postinfection. Statistical analysis of the PD₅₀s of SCH and FLC

TABLE 3. Proportion of mice infected with *Aspergillus* with negative lung cultures following prophylactic treatment with SCH 56592

SCH dose (mg/kg)	Strain	Total no. of mice ^a	% (no.) of mice with negative lung cultures ^b
25	<i>A. fumigatus</i> ND152	16	75 (12)
	<i>A. fumigatus</i> ND158	8	62 (5)
	<i>A. flavus</i> ND83	16	6 (1)
10	<i>A. fumigatus</i> ND152	16	63 (10)
	<i>A. fumigatus</i> ND158	8	50 (4)
	<i>A. flavus</i> ND83	16	0
5	<i>A. fumigatus</i> ND152	16	31 (5)
	<i>A. fumigatus</i> ND158	8	50 (4)
	<i>A. flavus</i> ND83	16	6 (1)
2.5	<i>A. fumigatus</i> ND152	16	6 (1)
	<i>A. fumigatus</i> ND158	8	0
	<i>A. flavus</i> ND83	16	0

^a The surviving mice were killed, and lung homogenates were diluted and spread onto SDA plates. The totals include the mice from two experiments with strains ND152 and ND83 and one experiment with strain ND158.
^b No growth was detected on SDA plates with a 10¹ dilution.

TABLE 4. Efficacies of therapeutic and prophylactic administration of SCH and FLC (both once daily) against systemic *C. albicans* infections in mice

<i>C. albicans</i> susceptibility and strain	Mice	PD ₅₀ (mg/kg)			
		Therapeutic administration (day 4) ^a		Prophylactic administration (day 7) ^b	
		SCH	FLC	SCH	FLC
FLC S					
C43	Normal	0.3	1.2	ND ^c	ND
C43	Irradiated	1.7	6.1	1.5	5.3
C84	Normal	0.6	4.3	ND	ND
C286	Normal	0.1	0.9	ND	ND
C65	Irradiated	0.04	2.6	ND	ND
C72	Irradiated	0.6	2.4	ND	ND
FLC S-DD					
C288	Normal	0.6	25	ND	ND
C288	Irradiated	ND	ND	7.8	>25
C342	Normal	7.1	30.5	ND	ND
FLC R					
C284	Normal	4.1	342	ND	ND
C284	Irradiated	ND	ND	7.0	431
C260	Normal	15.6	417	ND	ND
C310	Irradiated	ND	ND	19.4	204

^a PD₅₀ determined on day 4 postinfection.

^b PD₅₀ determined on day 7 postinfection.

^c ND, not done.

on the basis of their 95% confidence bounds indicated that SCH was significantly more active than FLC against FLC-S-DD strain C288 and the FLC-R strains ($P < 0.05$). The in vivo efficacy of SCH was further reflected in the reduced fungal burdens in the kidneys of the surviving mice (data not shown).

Prophylactic activity against systemic candidiasis. A systemic infection model with immunocompromised mice was used to evaluate the prophylactic efficacy of SCH against *C. albicans*. In these experiments, SCH was compared to FLC (Diflucan) administered once daily beginning at 24 h preinfection and continuing to day 7 postinfection against *C. albicans* C43 (FLC-S), C288 (FLC-S-DD), C284 (FLC-R), and C310 (FLC-R; FLC MIC, $>64 \mu\text{g/ml}$). The results in Table 4 show that SCH was efficacious against all strains (PD₅₀ range, 1.5 to 19.4 mg/kg), while FLC was active against C43 (PD₅₀, 5.3 mg/kg) but not against the less susceptible and resistant strains (PD₅₀s, >25 , 431, and 204 mg/kg against strains C288, C284, and C310, respectively). The survival-versus-time graph for FLC-R strain C284 shows that SCH at 50 and 25 mg/kg protected 100% of mice for 12 days postinfection, while FLC at 250 mg/kg was ineffective ($P < 0.01$) (Fig. 2). Other survival-versus-time graphs (data not shown) indicated that SCH at 10 and 25 mg/kg was more efficacious than FLZ at 25 mg/kg against strain C288 and FLZ at 100 mg/kg against strain C310, respectively ($P < 0.01$ for each comparison).

DISCUSSION

The potent in vitro activity of SCH against *Aspergillus*, *Candida*, and *Cryptococcus* was shown in the study described in this report. Other investigators have found SCH to have broad-spectrum in vitro activity not only against these fungi but also against *Blastomyces dermatitidis*, *Histoplasma capsulatum*, and other filamentous and dimorphic fungi (6, 9, 11, 19, 22, 24, 30, 32, 33, 34, 36).




FIG. 2. Effect of SCH and FLC (administered oral once daily) administered in a prophylactic regimen 1 day preinfection to 7 days postinfection on survival of immunocompromised mice systemically infected (with 5×10^6 CFU/mouse on day 0) with *C. albicans* C284 (FLC R). Dose levels (in milligrams per kilogram) are indicated. Controls were administered sWFI.

This report also highlights the in vivo efficacy of SCH against pulmonary *A. fumigatus* and *A. flavus* strains and systemic *C. albicans* strains (including strains with reduced susceptibility or resistance to FLC) in normal or immunocompromised mouse models of infection. In these studies, SCH was effective whether it was initially administered therapeutically after infection or prophylactically before infection. SCH was also reported by Graybill et al. (13) to be more effective than amphotericin B against invasive pulmonary aspergillosis in mice. In addition, Oakley et al. (31) found SCH to be more effective than ITC against disseminated aspergillosis in mice, while Kirkpatrick et al. (17) reported that SCH is more effective than ITC and is as effective as amphotericin B for the clearance of *Aspergillus* from tissues in a rabbit model of invasive aspergillosis.

In experimental infection models SCH was active not only against the more common opportunistic pathogens like *Aspergillus* and *Candida* but also against the less common fungi. Perfect et al. (32) reported that the activity of SCH was comparable to that of FLC against *C. neoformans* in a rabbit model of cryptococcal meningitis. Sugar and Liu (36) found that SCH was more effective than ITC and that the activity of SCH was similar to that of amphotericin B in prolonging survival and sterilizing the lungs of mice infected with *B. dermatitidis*. Lutz et al. (22) showed that SCH, but not FLC or ITC, cured survivors in a mouse model of systemic coccidioidomycosis. Connolly et al. (6) demonstrated in a pulmonary model of histoplasmosis in mice that SCH was more active than ITC and that the activity of SCH was similar to that of amphotericin B for sterilization of the lungs and spleens. SCH was also shown to increase the rate of survival and reduce the organ burdens in mice infected with *Fusarium solani* (21).

Pulmonary aspergillosis and disseminated candidiasis are recognized as serious complications and the leading causes of death among immunosuppressed patients, especially those with AIDS and those who have received bone marrow or liver transplants, for which only inadequate treatment or prophylaxis is available (2, 5, 7, 12, 16). Although prophylaxis with

FLC is used to prevent fungal infections in certain patient populations, there are major concerns about the development of resistance (4, 12, 15, 18, 23, 35, 37). ITC was recently evaluated for its prophylactic activity in a clinical trial and was found to reduce the incidence of systemic *Candida* infections and related deaths in neutropenic patients; however, it had no apparent efficacy in the prevention of *Aspergillus* infections (25). The need for more potent, broader-spectrum, longer-acting antifungal agents which are not associated with the emergence of resistance clearly exists. The broad-spectrum activity and experimental efficacy of SCH suggest that it could be effective for the treatment and prevention of severe fungal infections, such as aspergillosis and azole-refractory candidiasis, in high-risk individuals. In addition, the development of resistance to SCH may be a less likely event than with the development of resistance to other azole antifungal agents. Although SCH, like other azoles, blocks fungal sterol biosynthesis by inhibiting C-14 demethylation of lanosterol (H. Munayyer, K. J. Shaw, R. S. Hare, B. Salisbury, L. Heimark, B. Pramanik, and J. R. Greene, Abstr. 36th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F92, p. 115, 1996), Sanglard et al. (D. Sanglard, F. Ischer, and J. Bille, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-11, p. 48, 1997) found that SCH was insensitive to mutations in cytochromes known to hinder the binding of other azole drugs. However, the *C. albicans* ABC transporters Cdr1 and Cdr2 but not the major facilitators Ben and Flu1 were able to use SCH as a substrate when they were expressed in *Saccharomyces cerevisiae* (Sanglard et al., 37th ICAAC).

Preliminary pharmacodynamic analyses suggested that the area under the concentration-time curve is the most important factor in determining the efficacy of SCH in experimental infection models (G. H. Miller, D. Loebenberg, B. Antonacci, A. Cacciapuoti, E. L. Moss, Jr., F. Menzel, Jr., M. Michalski, C. Norris, R. Parmegiani, T. Yarosh-Tomaine, B. Yaremko, and R. S. Hare, Abstr. 36th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F94, p. 116, 1996). Nomeir et al. (29) reported that the concentrations of SCH in serum remained above the MIC for most filamentous fungi and yeasts 24 h following the administration of a single oral dose to various animal species, suggesting that once-daily administration of the compound should be a therapeutically effective dosage regimen. In mice, the mean concentrations of SCH in serum were >2 µg/ml for at least 12 h after oral administration of 20 mg/kg. In addition, SCH achieved a maximum concentration in serum of 6.3 µg/ml at 1 h after dosing, with an area under the concentration-time curve of 63.7 µg · h/ml and bioavailability of 47%. Dose-related increases in both the area under the concentration-time curve and the maximum concentration in serum were also observed in mice over a dose range of 20 to 160 mg/kg. SCH is being evaluated in Phase II and III clinical trials. Preliminary results from a phase II clinical trial indicated that SCH is an effective and well-tolerated alternative treatment for oropharyngeal and esophageal candidiasis in human immunodeficiency virus-infected patients unresponsive to FLC or ITC (D. Skiest, D. Ward, A. Northland, J. Reynes, and W. Greaves, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1162, p. 491, 1999).

ACKNOWLEDGMENT

We thank Ferdous Gheyas for statistical analysis.

REFERENCES

- Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. *Antimicrob. Agents Chemother.* **43**:2116–2120.
- Armstrong, D. 1989. Problems in management of opportunistic fungal dis-

- eases. *Rev. Infect. Dis.* **11**:S1591–S1599.
- Cacciapuoti, A., D. Loebenberg, R. Parmegiani, B. Antonacci, C. Norris, E. L. Moss, Jr., F. Menzel, Jr., T. Yarosh-Tomaine, R. S. Hare, and G. H. Miller. 1992. Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice. *Antimicrob. Agents Chemother.* **36**:64–67.
- Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. 1993. Correlation of in vitro fluconazole resistance of *Candida* isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. *Antimicrob. Agents Chemother.* **37**:2449–2453.
- Castaldo, P., R. J. Stratta, R. P. Wood, R. S. Markin, K. D. Patil, M. S. Shafer, A. L. Langnas, E. C. Reed, S. Li, T. J. Pillen, and B. W. Shaw, Jr. 1991. Clinical spectrum of fungal infections after orthotopic liver transplantation. *Arch. Surg.* **126**:149–156.
- Connolly, P., J. Wheat, C. Schnitzlein-Bick, M. Durkin, S. Kohler, M. Smedema, J. Goldberg, E. Brizendine, and D. Loebenberg. 1999. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. *Antimicrob. Agents Chemother.* **43**:322–328.
- Denning, D. 1998. Invasive aspergillosis. *Clin. Infect. Dis.* **26**:781–805.
- Emmons, C. W. 1977. *Medical mycology*, 3rd ed. Lea and Febiger, Philadelphia, Pa.
- Espinel-Ingroff, A. 1997. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. *J. Clin. Microbiol.* **36**:2950–2956.
- Fan-Havard, P., D. Capano, S. M. Smith, A. Mangia, and R. H. K. Eng. 1991. Development of resistance in *Candida* isolates from patients receiving prolonged antifungal therapy. *Antimicrob. Agents Chemother.* **35**:2302–2305.
- Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against *Candida albicans*, *Cryptococcus neoformans*, and other pathogenic yeasts. *Antimicrob. Agents Chemother.* **41**:180–183.
- Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shaddock, T. C. Shea, P. Stiff, D. J. Friedman, W. G. Powderly, J. L. Silber, H. Horowitz, A. Lichtin, S. N. Wolff, K. F. Mangan, S. M. Silver, D. Weisdorf, W. G. Ho, G. Gilbert, and D. Buell. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. *N. Eng. J. Med.* **326**:845–851.
- Graybill, J. R., R. Bocanegra, L. K. Najvar, M. F. Luther, and D. Loebenberg. 1998. SCH 56592 treatment of murine invasive aspergillosis. *J. Antimicrob. Chemother.* **42**:539–542.
- Gupta, A. K., D. N. Sauder, and N. H. Shear. 1994. Antifungal agents: an overview. Part II. *J. Am. Acad. Dermatol.* **30**:911–933.
- Havliir, D. V., M. P. Dube, J. A. McCutchan, D. N. Forthal, C. A. Kemper, M. W. Dunne, D. M. Parenti, P. N. Kumar, A. C. White, Jr., M. D. Witt, S. D. Nightingale, K. A. Sepkowitz, R. R. MacGregor, S. H. Cheeseman, F. J. Torriani, M. T. Zelasky, F. R. Sattler, and S. A. Bozzette. 1998. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. *Clin. Infect. Dis.* **27**:1369–1375.
- Khoo, S. H., and D. W. Denning. 1994. Invasive aspergillosis in patients with AIDS. *Clin. Infect. Dis.* **19**:S41–S48.
- Kirkpatrick, W. R., R. K. McAtee, A. W. Fothergill, D. Loebenberg, M. G. Rinaldi, and T. F. Patterson. 2000. Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis. *Antimicrob. Agents Chemother.* **44**:780–782.
- Law, D., C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. L. Keaneey, and D. W. Denning. 1994. High prevalence of antifungal resistance in *Candida* spp. from patients with AIDS. *J. Antimicrob. Chemother.* **34**:659–668.
- Law, D., C. B. Moore, and D. W. Denning. 1997. Activity of SCH 56592 compared with those of fluconazole and itraconazole against *Candida* spp. *Antimicrob. Agents Chemother.* **41**:2310–2311.
- Loebenberg, D., A. Cacciapuoti, R. Parmegiani, E. L. Moss, Jr., F. Menzel, Jr., B. Antonacci, C. Norris, T. Yarosh-Tomaine, R. S. Hare, and G. H. Miller. 1992. In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304. *Antimicrob. Agents Chemother.* **36**:498–501.
- Lozano-Chiu, M., S. Arikian, V. L. Paetznick, E. J. Anaissie, D. Loebenberg, and J. H. Rex. 1999. Treatment of murine fusariosis with SCH 56592. *Antimicrob. Agents Chemother.* **43**:589–591.
- Lutz, J. E., K. V. Clemons, B. H. Aristizabal, and D. A. Stevens. 1997. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. *Antimicrob. Agents Chemother.* **41**:1558–1561.
- Maenza, J. R., W. G. Merz, M. J. Romagnoli, J. C. Keruly, R. D. Moore, and J. E. Gallant. 1997. Infection due to fluconazole-resistant *Candida* in patients with AIDS: prevalence and microbiology. *Clin. Infect. Dis.* **24**:28–34.
- Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. 1998. In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. *Mycopathologia* **141**:73–77.
- Menichetti, F., A. Del Favero, P. Martino, G. Bucaneve, A. Micozzi, C. Girmenia, G. Barbabietola, L. Pagano, P. Leoni, G. Specchia, A. Caiozzo, R. Raimondi, and F. Mandelli. 1999. Itraconazole oral solution as prophylaxis

- for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. *Clin. Infect. Dis.* **28**:250–255.
26. **National Committee for Clinical Laboratory Standards.** 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
 27. **National Committee for Clinical Laboratory Standards.** 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. Document M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
 28. **National Research Council.** 1996. NIH guide to the care and use of laboratory animals. National Academy Press, Washington, D.C.
 29. **Nomeir, A. A., P. Kumari, M. J. Hilbert, S. Gupta, D. Loebenberg, A. Cacciapuoti, R. Hare, G. H. Miller, C.-C. Lin, and M. N. Cayen.** 2000. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent in mice, rats, rabbits, dogs, and cynomolgus monkeys. *Antimicrob. Agents Chemother.* **44**:727–731.
 30. **Oakley, K. L., C. B. Moore, and D. W. Denning.** 1997. In vitro activity of SCH 56592 and comparison with activities of amphotericin B and itraconazole against *Aspergillus* spp. *Antimicrob. Agents Chemother.* **41**:1124–1126.
 31. **Oakley, K. L., G. Morrissey, and D. W. Denning.** 1997. Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **41**:1504–1507.
 32. **Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell.** 1996. In vitro and in vivo efficacies of the azole SCH56592 against *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* **40**:1910–1913.
 33. **Pfaller, M. A., S. Messer, and R. N. Jones.** 1997. Activity of a new triazole, SCH 56592, compared with those of four other antifungal agents tested against clinical isolates of *Candida* spp. and *Saccharomyces cerevisiae*. *Antimicrob. Agents Chemother.* **41**:233–235.
 34. **Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh.** 1998. In vitro susceptibilities of *Candida* bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole. *Antimicrob. Agents Chemother.* **42**:3242–3244.
 35. **Sangeorzan, J. A., S. F. Bradley, H. Xiaogang, L. T. Zarins, G. L. Ridenour, R. N. Tiballi, and C. A. Kauffman.** 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. *Am. J. Med.* **97**:339–346.
 36. **Sugar, A. M., and X.-P. Liu.** 1996. In vitro and in vivo activities of SCH 56592 against *Blastomyces dermatitidis*. *Antimicrob. Agents Chemother.* **40**:1314–1316.
 37. **Troillet, N., C. Durussel, J. Bille, M. P. Glauser, and J. P. Chave.** 1993. Correlation between in vitro susceptibility of *Candida albicans* and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. *Eur. J. Clin. Microbiol. Infect. Dis.* **12**:911–915.
 38. **Walsh, T. J., and P. A. Pizzo.** 1988. Nosocomial fungal infections: a classification for hospital-acquired infections and mycoses arising from endogenous flora and reactivation. *Annu. Rev. Microbiol.* **42**:517–545.